Group 1 - The core viewpoint emphasizes the importance of high-quality development for listed companies in Hebei, driven by a collaborative approach involving multiple stakeholders [1] - The Hebei Securities Regulatory Bureau has initiated a "three-level linkage" mechanism to enhance the efficiency of company visits, resulting in a coverage rate of 85% among listed companies [2] - A total of 70 listed companies have been visited, with 33 issues resolved, showcasing the effectiveness of the initiative [2] Group 2 - The collaborative model integrates regulatory, service, financial, and media resources to support companies, with a focus on policy alignment and financial service customization [3] - The initiative encourages companies to focus on core business areas, enhance market value management, and improve investor communication [3][4] - Specific industries such as electronics and biomedicine are prioritized for visits, with tailored guidance provided to address unique challenges faced by companies [4] Group 3 - Future plans include expanding the coverage of company visits to achieve full coverage within the year and establishing a tracking system for issue resolution [5] - The goal is to leverage capital market policies to support economic growth in Hebei, contributing to the province's development [5]

Group 1 - The revenue composition of North China Pharmaceutical for the year 2024 is as follows: chemical preparations account for 44.02%, chemical raw materials account for 26.72%, biological preparations account for 16.36%, pharmaceutical intermediates account for 6.23%, and pharmaceutical and other logistics trade account for 4.61% [1] Group 2 - As of the announcement date, the total external guarantees provided by North China Pharmaceutical and its subsidiaries amount to approximately 1.757 billion yuan, which represents 32.6% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The company has provided guarantees totaling approximately 1.667 billion yuan for its subsidiaries, accounting for 30.93% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The amount of guarantees provided to entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for the year 2024 [3]

证券代码：600812 证券简称：华北制药 公告编号：临 2025-044 华北制药股份有限公司 关于为下属子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 担保对象一 | 被担保人名称 | | 华北制药集团先泰药业有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 8,000 | 万元 | | | | 实际为其提供的担保余额 | 12,000 | 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | √否 | □不适用：_________ | | 担保对象二 | 被担保人名称 | | 华北制药华胜有限公司 | | | | 本次担保金额 | 5,000 | 万元 | | | | 实际为其提供的担保余额 | 20,000 | 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | ...

Core Viewpoint - North China Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Adenosylcobalamin Capsules (0.5mg) from the National Medical Products Administration, indicating the product's compliance with quality and efficacy standards for generic drugs [1][2]. Group 1: Drug Registration Details - The Drug Registration Certificate for Adenosylcobalamin Capsules (0.5mg) was approved on July 29, 2025, after being submitted for review in April 2024 [2][4]. - Adenosylcobalamin is primarily used for the prevention and treatment of Vitamin B12 deficiency and related conditions, such as megaloblastic anemia [2][5]. Group 2: Research and Development - The company has invested a total of 10.9382 million yuan in research and development for this product [3]. - The product is expected to be produced and marketed following the receipt of the registration certificate [4]. Group 3: Market Situation - A total of 27 companies, including North China Pharmaceutical, hold the Drug Registration Certificate for Adenosylcobalamin Capsules (0.5mg) in China [5]. - The sales volume for the capsule form is projected to be approximately 29,000 units in 2024, with total sales across all forms expected to reach around 1.5 billion units, reflecting a 19% increase from 2023 [5]. Group 4: Impact on the Company - The approval of the Drug Registration Certificate enhances the company's product pipeline in hematology and hematopoietic system medications, meeting the basic requirements for centralized procurement bidding [6].

证券日报网讯 7月29日晚间，华北制药发布公告称，近日，公司收到国家药品监督管理局核准签发的腺 苷钴胺胶囊（0.5mg）的《药品注册证书》。 （文章来源：证券日报） ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Adenosylcobalamin capsules (0.5mg), which are expected to have significant therapeutic benefits in treating neurological conditions [1] Company Summary - The approved product, Adenosylcobalamin capsules, is designed to inhibit abnormal fat synthesis in nerve myelin, block the occurrence and development of nerve fiber demyelination, and promote the synthesis of proteins and lipids to repair damaged nerves [1] - The capsules also lower abnormal TNFα levels, inhibit the occurrence of SACD, participate in the tricarboxylic acid cycle, and promote the metabolism of three major substances to maintain normal cellular functions [1] - The product normalizes glutathione levels to protect nerve cells and participates in heme synthesis to improve anemia [1] - The company has invested a total of 10.9382 million yuan in research and development for this product to date (unaudited) [1]

Core Viewpoint - North China Pharmaceutical has received the drug registration certificate for Adenosylcobalamin capsules (0.5mg) from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product line [1] Group 1: Company Developments - The company announced the approval of Adenosylcobalamin capsules, which are primarily used for the prevention and treatment of Vitamin B12 deficiency [1] - The product is also indicated for supplementation when dietary intake of Vitamin B12 is insufficient and for treating megaloblastic anemia [1]

Core Viewpoint - North China Pharmaceutical (600812.SH) has received approval from the National Medical Products Administration for the registration certificate of Adenosylcobalamin capsules (0.5mg) [1] Group 1: Product Information - Adenosylcobalamin can inhibit abnormal fat synthesis in nerve myelin, blocking the occurrence and development of nerve fiber demyelination [1] - It promotes protein and lipid synthesis, repairing damaged nerves, and lowers abnormal TNFα levels, inhibiting the occurrence of SACD [1] - The product participates in the tricarboxylic acid cycle, promoting the metabolism of three major substances, and maintains normal cell function [1] Group 2: Medical Applications - Adenosylcobalamin is primarily used for the prevention and treatment of vitamin B12 deficiency, especially when dietary intake is insufficient due to conditions like consumptive diseases, hyperthyroidism, pregnancy, and lactation [1] - It is also indicated for megaloblastic anemia and other related conditions [1]

Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for Adenosylcobalamin capsules (0.5mg) from the National Medical Products Administration, indicating the product's compliance with basic procurement bidding conditions and its efficacy equivalent to the original product [1] Group 1: Product Approval and Market Impact - The newly approved product is primarily used for the prevention and treatment of Vitamin B12 deficiency, which is increasingly needed due to insufficient dietary intake, as well as for megaloblastic anemia [1] - The approval enhances the company's product pipeline in blood and hematopoietic system medications, filling a gap in their offerings [1] Group 2: Industry Considerations - The sales of formulation products are subject to uncertainties due to potential changes in domestic pharmaceutical industry policies and market environment [1]

Group 1 - The core point of the article is that Huabei Pharmaceutical has received the drug registration certificate for Adenosylcobalamin capsules from the National Medical Products Administration [2] - The revenue composition for Huabei Pharmaceutical in 2024 is as follows: Chemical preparations account for 44.02%, chemical raw materials account for 26.72%, biological preparations account for 16.36%, pharmaceutical intermediates account for 6.23%, and pharmaceutical and other logistics trade account for 4.61% [2]